<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966329</url>
  </required_header>
  <id_info>
    <org_study_id>MARAVI-SWITCH</org_study_id>
    <nct_id>NCT00966329</nct_id>
  </id_info>
  <brief_title>Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects</brief_title>
  <official_title>Pilot Study to Assess the Safety and Efficacy of Switching the Nnrti or pi to Maraviroc in Hiv-1-infected Subjects With Persistent Viremia Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with HIV-1 infection on HAART regimen including 2 NRTI/NtRTIs plus one of the
      following : 1 PI/ritonavir or ATV/unboosted or 1 NNRTI, will be randomized to switch from the
      NNRTI/PI to maraviroc (300 mg /12 h) or to continue with the same approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 48 week randomized, prospective, controlled, open-label, proof-of-concept pilot
      clinical trial.

      Patients with HIV-1 infection on HAART regimen including 2 NRTI/NtRTIs plus one of the
      following : 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir
      /ritonavir, tipranavir/ritonavir, darunavir/ritonavir) or ATV/unboosted (in a regimen without
      tenofovir) or 1 NNRTI (nevirapine or efavirenz).

      Patients will be randomized to switch from the NNRTI/PI to maraviroc (300 mg /12 h) or to
      continue with the same approach.

      The primary endpoint would be the percentage of patients who maintain virological suppression
      at week 48.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to virological failure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of lipid-lowering drugs</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the SCORE equation</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 / CD8 cell counts</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral resistance and viral tropism</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients who withdraw</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>48 weeks</time_frame>
    <description>Total cholesterol levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>48 weeks</time_frame>
    <description>HDL-cholesterol levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>48 weeks</time_frame>
    <description>LDL-cholesterol levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>48 weeks</time_frame>
    <description>Triglyceride levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>to switch from the NNRTI/PI to maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>to switch from the NNRTI/PI to maraviroc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>to continue with the same approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>to continue with the same approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc</intervention_name>
    <description>HAART regimen including 2 NRTI/NtRTIs plus maraviroc</description>
    <arm_group_label>to switch from the NNRTI/PI to maraviroc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>HAART regimen including 2 NRTI/NtRTIs plus one of the following :
1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)
or ATV/unboosted (in a regimen without tenofovir)
or 1 NNRTI (nevirapine or efavirenz).</description>
    <arm_group_label>to continue with the same approach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infected adults (=/+18 years old).

          2. Patient having a diagnosis of HIV infection, on stable HAART including 2 NRTI/NtRTIs
             plus one of the following: 1 PI/ritonavir or ATV/unboosted or 1 NNRTI.

          3. Undetectable plasma HIV-1 RNA (VL &lt; 50 copies/mL) while on HAART.

          4. Patient having at least one of the following conditions:

               -  Antiretroviral-related gastrointestinal disturbances, or

               -  Low patient's satisfaction associated with the current regimen posology
                  (ritonavir use, ritonavir intolerance…), or

               -  Any toxicity drug related.

          5. Nadir CD4 cell count &gt; 350 cells/mm3.

          6. Absence of resistance mutations in the RT or PR by (TrugeneTM)

          7. Good treatment adherence.

          8. Voluntary written informed consent.

        Exclusion Criteria:

          1. Virologic failure to a previous antiretroviral regimen.

          2. Any antiretroviral resistance mutation in a previous resistance test.

          3. Dual/mixed or X4 viruses detected at any time point, including the pre-treatment
             ES-Trofile test of the PBMC test done before treatment switch.

          4. Acute infections or uncontrolled chronic infection in the 2 months previous to the
             inclusion.

          5. Pregnancy or fertile women willing to be pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugènia Negredo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lluita contra la Sida Foundation, HIV Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lluita contra la Sida Foundation, HIV Unit, Irsi Caixa Foundation</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lluita contra la Sida Foundation, HIV Unit</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2009</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Germans Trias i Pujol Hospital</investigator_affiliation>
    <investigator_full_name>Sílvia Gel</investigator_full_name>
    <investigator_title>Dra. Eugenia Negredo</investigator_title>
  </responsible_party>
  <keyword>Switching</keyword>
  <keyword>Maraviroc</keyword>
  <keyword>Virological efficacy</keyword>
  <keyword>Lipid profile</keyword>
  <keyword>Tropism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

